Grape Seed Extract for Early Stage Lung Cancer
Trial Summary
What is the purpose of this trial?
Lung cancer is the leading cause of cancer death in the country, surpassing deaths caused by colorectal, prostate and breast cancers combined. Veterans are at higher risk of lung cancer due to the higher rate of smoking and environmental toxin exposures. The lack of effective therapy for lung cancer provides the impetus to search for alternative, safe, and effective treatment agents to improve treatment strategy against lung cancer, enhance the probability of a cure and reduce recurrence. Based on encouraging preclinical and clinical findings from an early phase I lung cancer prevention study, using a special formulation of a standardized grape seed extract with enhanced absorption called leucoselect phytosome (LP), the purpose of this new CSR\&D Merit Review project is to evaluate the potential usefulness of LP for pre-surgical treatment of early stage lung cancer patients in a phase IIa clinical trial. Findings from this study may set the stage for larger, confirmatory trials in the near future.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications that affect cytochrome P450 3A4 unless an alternative can be provided. If you are on such medications, you may need to switch to a different one.
What data supports the effectiveness of the treatment Leucoselect Phytosome for early-stage lung cancer?
Is grape seed extract safe for humans?
What makes the treatment Leucoselect Phytosome unique for early stage lung cancer?
Leucoselect Phytosome is unique because it combines grape seed extract with soy phospholipids to enhance absorption, and it has shown potential in reducing cell proliferation in the lungs and increasing beneficial omega-3 fatty acids and anti-inflammatory compounds in the blood, which may help prevent lung cancer in smokers.12678
Research Team
Jenny T Mao, MD
Principal Investigator
VA San Diego Healthcare System, San Diego, CA
Eligibility Criteria
This trial is for early stage lung cancer patients who can consent, have a good performance status (0-1), normal blood counts and liver function, and lesions likely to be lung cancer. They must not have advanced respiratory disease, be pregnant or breastfeeding, take certain drugs affecting the liver enzyme P450 3A4, or consume more than one glass of wine daily.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 2-3 weeks of oral LP treatment before surgical resection
Surgery
Surgical resection of tumors with collection of post-treatment samples
Follow-up
Post-surgery follow-up to monitor safety and effectiveness
Treatment Details
Interventions
- Leucoselect Phytosome
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor